Diabetic Macular Edema Infographics
Diabetic Macular Edema Market

Diabetic Macular Edema (DME) is triggered by Diabetic Retinopathy (DR), a well-known complication of diabetes. Diabetic Macular Edema occurs when excess fluid starts to build up in the macula of the eye. Diabetic Macular Edema can have symptoms like dark spots, blurred vision, double vision, colours can fade and people can find it difficult to see glare.


Some of Diabetic Macular Edema Facts

  • Diabetic Retinopathy is the most prevalent diabetic eye disease.
  • Diabetic Retinopathy is the leading cause of irreversible blindness in people in their working years.
  • All people with Type 1 or Type 2 diabetes are at risk for Diabetic Retinopathy and Diabetic Macular Edema.
  • The longer a person has diabetes, the risk of developing Diabetic Retinopathy or Diabetic Macular Edema increases significantly.
  • Nearly 80% of patients with Type 1 diabetes will have developed Diabetic Retinopathy after living with diabetes for 15 years.
  • There are 50% chances that patients with Type 2 diabetes will develop Diabetic Retinopathy after living with diabetes for around 20 years.


Diabetic Macular Edema Epidemiology Segmentation

  • Total Diabetic Macular Edema Prevalent Cases
  • Total Diagnosed Diabetic Macular Edema Prevalent cases
  • Gender-specific Diabetic Macular Edema Diagnosed Prevalent Cases
  • Age-specific Diagnosed Diabetic Macular Edema Prevalent Cases
  • Subgroups-Specific Diagnosed Diabetic Macular Edema Prevalent Cases
  • Diabetic Macular Edema Treated cases


 Diabetic Macular Edema Epidemiological Insights Observed in 2020

  • The total Diabetic Macular Edema prevalent population in the 7MM was observed to be 1,862,529.
  • In 2020, the United States had the largest incident population of Diabetic Macular Edema in 7MM.
  • The number of Diabetic Macular Edema cases in Germany was observed to be 220,533.
  • The number of Diabetic Macular Edema prevalent cases in France was observed to be 59,215.
  • The total Diabetic Macular Edema treated cases in the 7MM were observed to be 437,508.


Diabetic Macular Edema Market Insight

The Diabetic Macular Edema market is expected to grow at a CAGR of 3.2% during the study period [2018-2030] in the 7MM. 


Diabetic Macular Edema Market Drivers 

  • Increasing changes in lifestyle
  • Addressing barriers to screening
  • Personalization of treatment


Diabetic Macular Edema Market Barriers

  • Exorbitant cost
  • Shortage of trained ophthalmologists
  • Lack of awareness of eye conditions


Diabetic Macular Edema Emerging Drugs

The emerging drugs of the Diabetic Macular Edema market are

  • ADVM-022
  • GB-102
  • Faricimab (RG 7716)
  • Beovu (RTH258; brolucizumab)
  • KVD001
  • APX3330
  • THR-149
  • YD-312
  • LKA651
  • Abicipar
  • Luminate (ALG-1001, Risuteganib)
  • KSI-301
  • Xipere (CLS-TA), and several others


Diabetic Macular Edema Companies 

The key players working in the Diabetic Macular Edema market are

  • Adverum Biotechnologies
  • Graybug Vision
  • Roche
  • Novartis
  • KalVista Pharmaceuticals
  • Ocuphire Pharma
  • Oxurion
  • YD Life Science
  • Novartis
  • Allergan (AbbVie)
  • Molecular Partners
  • Allergo Ophthalmics 
  • Bausch Health
  • Kodiak Sciences
  • Clearside Biomedical, and several others